Minjung Kim

Dr. Minjung Kim

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2023 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
MDMatthew Dean
Matthew Dean
MKMinjung Kim
Minjung Kim
SDSharon Dimauro
Sharon Dimauro
STSusan Tannenbaum
Susan Tannenbaum
GGGarth Graham
Garth Graham
AKAgnes S Kim
Agnes S Kim
Background: Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. Methods: This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m2) and low exposure groups. Results: The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. Conclusions: The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers.

30 September 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MKMinjung Kim
Minjung Kim
STSara R. Tabtabai
Sara R. Tabtabai
RARobert H. Aseltine
Robert H. Aseltine

4 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
KDKevin Dieckhaus
Kevin Dieckhaus
MKMinjung Kim
Minjung Kim
JSJian-Bing Shen
Jian-Bing Shen
TLTina S. Liang
Tina S. Liang
MKMichael J. Kleinberg
Michael J. Kleinberg
BLBruce T. Liang
Bruce T. Liang
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs.

1 January 2020 in Production
Verified
Journal Article
Open access
PDF file
EDEralp Dogu
Eralp Dogu
MKMinjung Kim
Minjung Kim
Paper aims Based on challenges faced in real SPC application, this paper considers implementation and performance of self-starting methodology in multivariate process monitoring. Originality Traditional omnibus charts depend on in-control process parameters while parameters are generally known. However, in real settings, this information may not exist. This paper proposes and compares novel methods to overcome this difficulty. Research method This paper introduces, evaluates the performance and implements multivariate self-starting charts (SSMEC, SSMELR, and SSMME) for multivariate process monitoring. Main findings Proposed SSMME chart is the best choice in real application because it proves better performance in response to various simulation scenarios and gives diagnostic tools for further analysis. Implications for theory and practice The main contributions are the comparison of different self-starting approaches and introducing a novel multivariate self-starting chart that are suitable in real process monitoring and illustrate the benefit of the selected SPC chart with hypertension monitoring.

10 August 2024 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MKMinjung Kim
Minjung Kim
GLGrace Lee
Grace Lee
GLGian Lima
Gian Lima
OMOsama Mukarram
Osama Mukarram
SCSamuel Crooks
Samuel Crooks
AKAgnes S Kim
Agnes S Kim

21 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MKMinjung Kim
Minjung Kim
JYJun Yan
Jun Yan
JWJason H. Wasfy
Jason H. Wasfy
RARobert H. Aseltine
Robert H. Aseltine
Background: Heart failure (HF) is a major contributor to inpatient hospital utilization, with persistently high 30-day readmission rates. Existing prediction tools are frequently restricted to primary-diagnosis HF admissions, potentially excluding clinically relevant HF-related hospitalizations. Objectives: To develop and validate risk prediction models using machine learning (ML)-based risk prediction models to predict 30-day readmissions among patients with HF using the Kansas Health Information Network, a statewide health information exchange. Methods: This retrospective cohort study analyzed HF hospitalizations using predictors including demographics, comorbidities, laboratory results, medications, clinical quality metrics for diabetes and kidney disease management, and prior healthcare utilization. Five ML models, including regularized logistic regression, random forest, extreme gradient boosting, categorical boosting, and deep neural network, were trained using stratified 5-fold cross-validation. Model performance was evaluated on an independent test set using the area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), misclassification rate (MCR), and Brier score. Results: Among 2,734 HF patients, the 30-day readmission rate was 27%. The XGBoost model achieved the best discrimination (AUROC=0.75; AUPRC=0.58; MCR=0.21). Patients in the highest-risk decile had a positive predictive value of 76%, accounted for approximately one-third of all 30-day readmissions, and had a 3.3-fold enrichment compared with baseline risk. The key predictors included prior hospital utilization, diabetes and kidney disease management indicators, and comorbidity burden. Conclusions: Risk stratification using routinely collected clinical data identified a subgroup at elevated risk for 30-day readmission. These findings support the potential role of data-driven risk prediction to inform targeted transitional care. CLINICAL PERSPECTIVES: What is New?: This study is among the first to utilize health information exchange data to develop machine learning models for predicting 30-day heart failure readmissions, including patients with HF as either a primary or secondary diagnosis. Unlike prior models restricted to primary HF admissions, this approach includes hospitalizations in any diagnosis position, reflecting real-world acute-care utilization. Notably, our machine learning model correctly identified approximately three in four patients classified as high-risk in the top decile of predicted scores, highlighting its ability to identify individuals at greatest likelihood of early readmission What are the Clinical Implications?: Accurately identifying a group of high-risk patients has meaningful implications for care delivery. By correctly capturing actual readmissions within a small, prioritized segment of the population, ML-driven risk stratification can guide clinicians and care management teams in targeting transitional care resources where they are most needed. Such focused intervention strategies may allow for efficient targeting of limited health care resources, improve post-discharge outcomes, enhance operational efficiency, and potentially reduce preventable HF readmissions.